Stockscreener 앱 받기
32.71
2.44%
0.78
시간 외 거래:
32.80
0.09
+0.28%
전일 마감가:
$31.93
열려 있는:
$32
하루 거래량:
866.58K
Relative Volume:
1.27
시가총액:
$2.04B
수익:
$32.08M
순이익/손실:
$-169.77M
주가수익비율:
-11.51
EPS:
-2.8418
순현금흐름:
$-147.70M
1주 성능:
+13.34%
1개월 성능:
-0.94%
6개월 성능:
+0.96%
1년 성능:
+146.87%
1일 변동 폭
$31.62
$32.84
1주일 범위
$28.19
$33.09
52주 변동 폭
$12.86
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
32.71 | 1.83B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-05 | 개시 | Guggenheim | Buy |
| 2026-01-05 | 재개 | Chardan Capital Markets | Buy |
| 2025-07-18 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
EcoR1 Capital LLC Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates - BioSpace
Stoke Therapeutics Inc (STOK) Cash Flow - TradingKey
Stoke Therapeutics Inc (STOK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Stoke Therapeutics Inc (STOK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Stoke Therapeutics Inc (STOK) Institutional Confidence - TradingKey
Troluce Capital Advisors LLC Buys Shares of 652,800 Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Stoke Therapeutics Inc (STOK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
STOK|Stoke Therapeutics Inc|Price:29.320|Chg%:+0.020 - TradingKey
Stoke Therapeutics Inc (STOK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Granahan Investment Management LLC Has $10.93 Million Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. Revenue Breakdown – NASDAQ:STOK - TradingView
Siren L.L.C. Sells 252,000 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
(STOK) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Stoke Therapeutics (STOK) Edges Higher, Testing Resistance at $30.41ADD Alert - dars.gov.et
Stoke Therapeutics Inc (STOK) - MSN
Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch (NASDAQ:STOK) - Seeking Alpha
Stoke Therapeutics Chief Scientific Officer Thomas McCauley files initial beneficial ownership statement - Bitget
Form 4 Stoke Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Form 4 Stoke Therapeutics Inc For: 17 July - Investing.com India
Stoke Therapeutics (STOK) director gifts 303,190 options to trust - Stock Titan
Stoke Therapeutics (STOK) awards 225,000 stock options to Chief Scientific Officer - Stock Titan
Stoke Therapeutics (STOK) CSO Thomas McCauley files initial insider report - Stock Titan
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 16, 2026 - BioSpace
Stoke Therapeutics grants CSO McCauley options for 225,000 shares at $29.91 each - Bitget
Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group - MarketBeat
Stoke Therapeutics (STOK) Declines Slightly as Stock Consolidates Near ResistanceStock Analysis - dars.gov.et
Jefferies Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $44 - Moomoo
Stoke Therapeutics appoints Thomas McCauley as CSO By Investing.com - Investing.com India
Stoke Tx appoints Thomas McCauley as CSO - The Pharma Letter
Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer - citybiz
Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential - Investing.com UK
Stoke Therapeutics Taps Dr. Thomas McCauley as Chief Scientific Officer - Contract Pharma
Stoke Therapeutics Announces Appointment of Thomas McCauley as Chief Scientific Officer - marketscreener.com
Stoke Therapeutics appoints Thomas McCauley as CSO - Investing.com
Goldman Sachs Initiates Coverage on Stoke Therapeutics With Buy Rating, $44 Price Target - marketscreener.com
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer - Business Wire
STOK Initiates Coverage On Goldman Sachs -- Price Target Announced at $44 - GuruFocus
Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential By Investing.com - Investing.com South Africa
Candriam S.C.A. Has $16.35 Million Stake in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - Moomoo
Stoke Therapeutics, Inc. Actuals & Estimates (DUS:0GT) - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Stoke Therapeutics Announces Updates to Timelines for the Complet - The National Law Review
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Stoke Therapeutics highlights antisense pipeline as genetic medicine interest grows - AD HOC NEWS
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.84%
0.86%
자본화:
|
볼륨(24시간):